All In Biotech

Drug Trial Radar · NCT05580562

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

510

Planned (sponsor's estimate)

Start

Jan 23, 2023

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
Chimerix, Inc.
First posted
Oct 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.

Conditions

  • H3 K27M
  • Glioma

Interventions

  • Dordaviprone (ONC201)Drug

    Participants ≥ 52.5 kg will receive 625 mg of dordaviprone (5 × 125-mg capsules) dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments.

  • Dordaviprone (ONC201) + PlaceboDrug

    Participants ≥ 52.5 kg will receive 625 mg of dordaviprone (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments

  • PlaceboOther

    Participants will receive placebo (same number of capsules as the dordaviprone dose) on dosing days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: From date of randomization until date of death from any cause, assessed up to approximately 44 months

Locations

162 sites in 18 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Phoenix, Arizona · Completed

  • Barrow Neurological Institute

    Phoenix, Arizona · Active not recruiting

  • Phoenix Childrens Hospital

    Phoenix, Arizona · Completed

  • Mayo Clinic Arizona

    Phoenix, Arizona · Completed

  • UC San Diego Moores Cancer Center

    La Jolla, California · Active not recruiting

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California · Completed

  • UCLA University of California Los Angeles

    Los Angeles, California · Completed

  • Children's Hospital of Orange County

    Orange, California · Completed

  • University of California Irvine

    Orange, California · Active not recruiting

  • UCSF Benioff Children's Hospital

    San Francisco, California · Active not recruiting

  • University of California San Francisco

    San Francisco, California · Active not recruiting

  • Providence Saint John's Cancer Institute

    Santa Monica, California · Active not recruiting

  • Stanford Cancer Center

    Stanford, California · Completed

  • Yale University

    New Haven, Connecticut · Active not recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Completed

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Active not recruiting

  • Miami Cancer Institute

    Miami, Florida · Active not recruiting

  • St Joseph's Children's Hospital of Tampa

    Tampa, Florida · Completed

  • Moffitt Cancer Center

    Tampa, Florida · Active not recruiting

  • Cleveland Clinic Florida

    Weston, Florida · Completed

  • Children's Healthcare of Atlanta

    Atlanta, Georgia · Completed

  • Kapi'olani Medical Center for Women and Children

    Honolulu, Hawaii · Completed

  • Feinberg School of Medicine Northwestern University

    Chicago, Illinois · Active not recruiting

  • Indiana University School of Medicine - Indianapolis

    Indianapolis, Indiana · Active not recruiting

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa · Active not recruiting

  • Norton Healthcare

    Louisville, Kentucky · Active not recruiting

  • Ochsner Medical Center - New Orleans

    New Orleans, Louisiana · Completed

  • University of Maryland School of Medicine

    Baltimore, Maryland · Completed

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts · Active not recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Active not recruiting

  • University of Michigan Hospital

    Ann Arbor, Michigan · Active not recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Active not recruiting

  • Mayo Clinic - Cancer Center - Rochester

    Rochester, Minnesota · Active not recruiting

  • Washington University School of Medicine/St. Louis Children's Hospital

    St Louis, Missouri · Active not recruiting

  • Benefis Hospital Sletten Cancer Institute

    Great Falls, Montana · Withdrawn

  • University of Nebraska Medical Center

    Omaha, Nebraska · Completed

  • Jersey Shore University Medical Center

    Neptune City, New Jersey · Active not recruiting

  • Overlook Medical Center

    Summit, New Jersey · Active not recruiting

  • Albany Medical Center

    Albany, New York · Completed

  • Children's Hospital at Montefiore Medical Center

    New York, New York · Completed

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.